Clinical trials: sponsored by Fox Chase Cancer Center
Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer.
- Conditions
- Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- Trial name
- NCT05923190
- Testing
- Enfortumab vedotin, Pembrolizumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fox Chase Cancer Center
Pulmonary Nodule, Multiple, Pulmonary Nodule, Solitary
Utility of CAML as Diagnostic for Early Stage Lung Cancer
Primary Objective Determine the prevalence of CAMLS in patients with pulmonary nodules. Secondary Objectives Determine the positive and negative predictive value of CAMLS in patients with pulmonary nodules who undergo biopsy.
- Trial name
- NCT03992183
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
This is a single-arm, open-label, non-randomized Phase II trial evaluating the efficacy of induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 18 weeks (6 cycles), followed by maintenance pembrolizumab in…
- Conditions
- Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial Carcinoma
- Trial name
- IMPROEV (NCT07221942)
- Testing
- Enfortumab vedotin, Pembrolizumab
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Fox Chase Cancer Center
Neoplasm
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
The overarching goal of the current study is to reduce the burden Asian American patients may feel are on their caregivers by designing and testing the feasibility and efficacy of a positive activity intervention designed to…
- Trial name
- CARE (NCT06782581)
- Testing
- Contribution to Caregivers Well-Being, Control
- Where
- United States
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Rectum Cancer, Adenocarcinoma
Adaptive Radiation Boost for Rectal Cancer
The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.
- Trial name
- ARBOR (NCT07221058)
- Testing
- Adaptive Radiotherapy Boost
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fox Chase Cancer Center
Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual…
- Conditions
- Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- INSITE (NCT06396533)
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Fox Chase Cancer Center
Neoplasm - Soft Tissue Pelvis Malignant Secondary, Malignant Neoplasm of Stomach
Adaptive Radiation for Abdominopelvic Metastases
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no…
- Trial name
- NCT05880667
- Testing
- Adaptive Stereotactic Body Radiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fox Chase Cancer Center
Colorectal Cancer (Diagnosis)
Fitbit Assessed PS in Colorectal Cancer
Primary Objective To assess the feasibility of activity tracking using Fitbit device in terms of compliance (defined as at least 75% of patients complying with instructions to wear the device, for at least 12 hours a day on at…
- Trial name
- NCT07084181
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Fox Chase Cancer Center
Lynch Syndrome
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
The goal of this study is to investigate that a common cholesterol lowering agent (atorvastatin) alone or combining with a nonsteroidal anti-inflammatory drug (aspirin) would reduce the risk of colorectal cancer (CRC) in…
- Trial name
- NCT04379999
- Testing
- Atorvastatin 20mg, Atorvastatin 20mg AND Aspirin 325 mg
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Small-cell Lung Cancer, Neuroendocrine Carcinoma
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
This is a non-randomized single-arm, two cohorts, phase II study of iadademstat in combination with weekly paclitaxel in patients with relapse/refractory SCLC or extrapulmonary G3 Neuroendocrine Carcinomas.
- Trial name
- NCT05420636
- Testing
- Iadademstat, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fox Chase Cancer Center
Cancer
Feasibility, Acceptability and Fidelity of Integrating a Navigation Intervention Into Tobacco Treatment Program
Patient Navigation is being included as part of a tobacco treatment program for cancer patients to help patients overcome barriers to quitting.
- Trial name
- NCT07072312
- Testing
- Adjuvant Patient Navigation for Tobacco Treatment
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Fox Chase Cancer Center
Carcinoma Breast Stage IV
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
The main purpose of this study is to see if Pembrolizumab in combination with chemotherapy (carboplatin and gemcitabine) is safe and effective in treating patients with metastatic triple negative breast cancer.
- Trial name
- NCT02755272
- Testing
- Pembrolizumab, Carboplatin, Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 87 people
- Sponsor
- Fox Chase Cancer Center
CIPN - Chemotherapy-Induced Peripheral Neuropathy, Pain
Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.
The investigators hypothesize that Scrambler therapy with duloxetine, compared to duloxetine-based usual care, will result in greater improvement in CIPN as measured by the BPI-Short Form.
- Trial name
- NCT06914557
- Testing
- Scrambler Therapy, Questionnaire and Physical Exam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fox Chase Cancer Center
Diffuse Large B Cell Lymphoma
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Patients suffering from diffuse large B-cell lymphoma (DLBCL) who relapse within 12 months of chemotherapy usually undergo salvage therapies, followed by autologous transplant with a low success rate.
- Trial name
- NCT03311958
- Testing
- Nivolumab, IV, 240 mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fox Chase Cancer Center
Cutaneous T-cell Lymphoma (CTCL)
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
This is a Phase I Trial to assess the feasibility of Romidepsin combined with Brentuximab Vedotin for patients requiring Systemic Therapy for Cutaneous T-cell Lymphoma.
- Trial name
- NCT02616965
- Testing
- Romidepsin, Brentuximab vedotin
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Tumors, Primary Neoplasm
Perioperative Risk Study
The primary objective of this trial is to determine if perioperative risk stratification and risk-based, protocol-driven management leads to a reduction in the rate of death or serious complications compared to standard…
- Conditions
- Tumors, Primary Neoplasm, Secondary Neoplasm, Surgery
- Trial name
- PRS (NCT02456389)
- Testing
- Preoperative risk stratification, Postoperative risk stratification, Risk-based, escalating levels of care
- Where
- United States
- Volunteers
- 1,456 people
- Sponsor
- Fox Chase Cancer Center
Liver Cancer
Liver Cancer Community Education
This study proposes to bridge the gap between evidence and action and combat rising liver cancer rates attributed to Hepatitis B and C infection in Philadelphia by identifying neighborhoods with higher than expected rates of…
- Trial name
- NCT04272619
- Testing
- LIVE-R Life Education
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Lymphoma, Indolent Non-hodgkin Lymphoma
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
This is a phase II pilot, single arm, open label study designed to assess the efficacy, safety, and feasibility of MRD adapted duration of BR for untreated or R/R iNHL.
- Trial name
- NCT06557330
- Testing
- Bendamustine, Rituximab
- Volunteers
- 24 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Breast Cancer
Couples' QOL in Metastatic Breast Cancer
The primary objectives of this study are to adapt and evaluate a sexual quality of life intervention in women with metastatic breast cancer and their partners.
- Trial name
- C-QOL (NCT05636943)
- Testing
- Adapted Intimacy Enhancement, Intimacy Facts and Resources
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Fox Chase Cancer Center
Cervical Cancer, Papilloma Viral Infection
Reducing Urban Cervical Cancer Disparities
This study uses a hybrid Type 1 effectiveness-implementation trial to operationalize and assess the efficacy of the Health Enhancement Resource System (HERS) intervention.
- Trial name
- NCT06416150
- Testing
- Stage 1 SOC, Stage 1 HERS, Stage 2 HERS
- Where
- 3 sites in United States
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center